Skip to main content

Page last checked

Glucagon/GLP-1 dual receptor agonist peptide (investigational) · dosing

Pemvidutide dosage: trial doses and later results

There is no approved dosing label for Pemvidutide. This chart maps published and sponsor-disclosed trial regimens—it is not an approved or recommended schedule.

The published trial tested 1.2–2.4 mg once weekly for 48 weeks in MOMENTUM (1.2, 1.8 or 2.4 mg). It enrolled 391 participants and ran as the 48-week MOMENTUM phase 2 obesity trial. Pemvidutide has no approved dosing label. One later readout studied 2.4 mg targets; each result shows its publication status, and missing dose steps stay unreported. Those are randomized study regimens, not a schedule for personal use.

Source: Altimmune 2024 Form 10-K — 48-week MOMENTUM phase 2 obesity results

What matters first

What trials tested
1.2–2.4 mg once weekly for 48 weeks in MOMENTUM (1.2, 1.8 or 2.4 mg)
Study size
391 participants
Approved schedule
No FDA-approved Pemvidutide dosing label exists.

Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewerReviewed 2026-08-17open the primary sources

What later trial readouts added

The company announced these newer results, but full peer-reviewed papers were not available when this was checked. Each study stays in its own table.

RECLAIM phase 2 alcohol-use-disorder trial

Adults with moderate or severe alcohol use disorder and BMI above 25 kg/m²

Company announcement
100 participants · 24 weeks · 2.4 mg or placebo once weekly
RECLAIM phase 2 alcohol-use-disorder trial Pemvidutide target doses and reported outcomes
TargetDose pathParticipants with a two-level reduction in WHO drinking-risk levelParticipants with zero heavy-drinking days during weeks 21–24Publication status
2.4 mg weeklyIntermediate steps not reported64.4%42.2%Result announced by the company
Placebo—34.8%17.4%Result announced by the company

The sponsor reported 4.20 fewer heavy-drinking days per week from baseline with pemvidutide, versus 2.75 with placebo. These topline results have not passed peer review. Registry: NCT06987513. Sources retrieved 2026-08-17.

The published trial dosing program

These are the once-weekly dose groups used in the published trial. The table prints only the dose detail the source supplies. They describe a randomized protocol under monitoring, not a recommended titration schedule.

◆ 48-week MOMENTUM phase 2 obesity trial391 participants · 48 weeks
Pemvidutide doses tested in the trial
ArmOnce-weekly dosePosition in the studied rangeHow the trial reached it
11.2 mgLowest arm studied—
21.8 mgIntermediate arm—
32.4 mgHighest arm studied—

Source: Altimmune 2024 Form 10-K — 48-week MOMENTUM phase 2 obesity results · retrieved 2026-08-17 · the paths above reproduce only the doses the source names. The source does not turn those paths into advice.

Average weight change after 48 weeks
Pemvidutide average weight change after 48 weeks, by dose group
Target-dose groupMean change at 48 weeksHow the paper reports it
1.2 mg weekly10.3% decreaseTarget-dose group
1.8 mg weekly11.2% decreaseTarget-dose group
2.4 mg weekly15.6% decreaseTarget-dose group
Placebo2.2% decreasePlacebo group

Source: Altimmune 2024 Form 10-K — 48-week MOMENTUM phase 2 obesity results · retrieved 2026-08-17. Only outcomes the cited paper reports for a named arm appear here; no missing result is estimated.

The study reports a range of 1.2–2.4 mg once weekly for 48 weeks in MOMENTUM (1.2, 1.8 or 2.4 mg). Doses outside that range were not studied in this trial and are not reported here at any strength of claim.

Pemvidutide dosage. There is no approved label. These are the arms of a 48-week momentum phase 2 obesity trial, not a schedule. It had 391 participants. The arms were 1.2 mg, 1.8 mg, 2.4 mg, each once a week. Source: the cited source.
The same arms rendered as a standalone chart, generated from the page above. It states on its face that there is no approved label. An image separated from this page would otherwise read as a schedule, which is exactly the error this page exists to avoid.

What each of these arms produced, with the placebo comparison →

Why there is no Pemvidutide dosage chart

A dosage chart is a regulatory artifact before it is an editorial one. It exists when an agency has reviewed a sponsor’s trials, agreed a schedule, and bound the manufacturer to a product of stated identity and potency. Pemvidutide has none of that yet.

One trial cannot prove long-term safety or show that the result applies to everyone. The highest dose tested is a study dose, not a target for personal use.

Pemvidutide is not FDA-approved.

It has no prescribing label or established dose. Its weight, liver and alcohol studies enrolled different groups and measured different results. The findings cannot be swapped between them.

Starting phase 3 does not mean a drug is approved.

Sites that publish a titration chart for a compound at this stage have built it by inference. They take a trial’s target dose and reverse-engineer a plausible ramp toward it. The result looks exactly like a supported schedule and should not be read as one. The table shows only the trial arms that were actually studied.

1Reference detailsHow the study tested each dose

How dosing works in this class

Why the dose escalates instead of starting where it ends

The dose climbs in steps for one reason: how well people tolerate it, not how well it works. The receptors that produce the effect you want are the same ones that slow your stomach down, and your gut reacts hardest when the exposure is new. Hold it steady and the reaction fades. Stepping up gradually is a way of using that — each step is a stretch of time for your body to settle at where it is before the next increase arrives.

The length of each step matters. Shortening it moves the next increase into a period when the body may not have adjusted. Labels and trial plans state the intervals that were tested. A faster ramp was not tested.

Why trial dose groups are not a dosing schedule

A dose-finding trial is an experiment about doses, not a recommendation of one. Its arms exist to spread people across a range so researchers can see the shape of the curve. Some arms are set deliberately low, where too little effect is expected. Others are set high, where people are expected to struggle. Reading the top arm as the target gets the design backwards: the reason for running the whole range was that nobody yet knew which part of it was right.

Trial doses came with screening, monitoring, a set schedule and drug of tested strength and purity. Removing a milligram figure from those conditions removes much of what made it meaningful. The table therefore shows what researchers tested, not a schedule to follow.

Questions about Pemvidutide dosing

What doses were used in the later Pemvidutide trials?

The later trial studied 2.4 mg weekly. Where the public sources do not name the intermediate steps, the table says so instead of reconstructing them. These are monitored trial protocols, not an approved schedule.

Are the latest Pemvidutide trial results peer reviewed?

No. The company announced the later results, but they have not been peer reviewed. The older dosing study below has been peer reviewed.

What are the typical Pemvidutide dosages?

The trial ran 3 once-weekly regimens between 1.2 mg and 2.4 mg for 48 weeks. An arm is a group a protocol assigned, not a dosage anybody settled on. These are study regimens, not an approved dosing schedule.

How fast can the Pemvidutide dose increase?

The trial ran as a 48-week momentum phase 2 obesity trial. The page’s own description is once weekly for 48 weeks in MOMENTUM (1.2, 1.8 or 2.4 mg). Nothing published here establishes what a faster ramp would produce.

What if side effects make the next step too hard?

The next increase is optional, not automatic. The label allows a longer stay at the current step when needed. A clinician decides what happens after a dose is hard to handle; the schedule alone cannot make that decision.

Does the starting Pemvidutide dose treat the condition?

Yes. One randomized group received 1.2 mg once weekly for 48 weeks and the group changed by an average of -10.3% by week 48. That proves the dose was studied; it does not make it an approved starting dose or a recommendation.

What is the highest Pemvidutide dose on the page?

The highest arm studied was 2.4 mg once weekly. It is simply the highest amount the trial tested. It is not a maximum dose, because no regulator has set one.

Why do some compounds here have a chart and others do not?

Because a chart is a claim about provenance, not a formatting choice. Where an FDA-approved label specifies a schedule, this site quotes it row by row and cites the label under the table. Where no label exists, the guide shows what trials tested and says plainly that it is not a schedule. For Pemvidutide, that is the 48-week momentum phase 2 obesity trial above.

The pemvidutide reactions reported most often

Frequency bands exactly as the pemvidutide source states them, with grouped figures kept grouped.

What backs the pemvidutide numbers, and what backs the rest

Every row states whether a label, a trial or nothing stands behind it, including Pemvidutide

The proceedings behind the pemvidutide note on this page

Newest entry first, with pemvidutide among them.

Where pemvidutide sits among the source-checked pages

See the strongest source available for every compound, with pemvidutide as context

How each pemvidutide claim is checked

Source definitions and the checks that enforce them, including the source for pemvidutide.

7primary sources, each with the day we read it — open the documents used on this page